SG11201901389XA - Combination therapy with glutaminase inhibitors - Google Patents

Combination therapy with glutaminase inhibitors

Info

Publication number
SG11201901389XA
SG11201901389XA SG11201901389XA SG11201901389XA SG11201901389XA SG 11201901389X A SG11201901389X A SG 11201901389XA SG 11201901389X A SG11201901389X A SG 11201901389XA SG 11201901389X A SG11201901389X A SG 11201901389XA SG 11201901389X A SG11201901389X A SG 11201901389XA
Authority
SG
Singapore
Prior art keywords
international
rule
glutaminase
seaport
california
Prior art date
Application number
SG11201901389XA
Inventor
Francesco Parlati
Keith Orford
Sam Whiting
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of SG11201901389XA publication Critical patent/SG11201901389XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/039544 Al 01 March 2018 (01.03.2018) W I P0 I P C T (51) International Patent Classification: A61K 31/433 (2006.01) C07D 417/02 (2006.01) Declarations under Rule 4.17: A61K 31/501 (2006.01) CO7D 417/14 (2006.01) — of inventorship (Rule 4.17(iv)) A61P 35/00 (2006.01) Published: (21) International Application Number: — with international search report (Art. 21(3)) PCT/US2017/048581 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) 25 August 2017 (25.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/379,604 25 August 2016 (25.08.2016) US (71) Applicant: CALITHERA BIOSCIENCES, INC. [US/US]; 343 Oyster Point Boulevard, Suite 200, South San Francisco, California 94080 (US). (72) Inventors: PARLATI, Francesco; 1035 York Street, San _ Francisco, California 94110 (US). ORFORD, Keith; 3819 Charter Club Drive, Doylestown, Pennsylvania 18902 (US). — = WHITING, Sam, H.; 8920 Sand Point Way NE, Seattle, Washington 98115 (US). = Agent: HALSTEAD, David, P. et al.; Foley Hoag (74) — LLP, Seaport West, 155 Seaport Boulevard, Boston, MA _ = 02210-2600 (US). Designated States (unless otherwise indicated, for every = (81) — kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = = = = MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, — OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every = (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = — 1-1 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 71' 71' kin tz . M © (54) Title: COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS --.... ,1 (57) : The invention relates to methods of treating cancer or myeloproliferative diseaseswith a combination of a glutaminase 0 inhibitor and an anticancer agent selected from cabozantinib, crizotinib, and axitinib. The invention further relates to methods of treating N cancer or myeloproliferative diseases that are resistant to one or more anticancer agents.
SG11201901389XA 2016-08-25 2017-08-25 Combination therapy with glutaminase inhibitors SG11201901389XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662379604P 2016-08-25 2016-08-25
PCT/US2017/048581 WO2018039544A1 (en) 2016-08-25 2017-08-25 Combination therapy with glutaminase inhibitors

Publications (1)

Publication Number Publication Date
SG11201901389XA true SG11201901389XA (en) 2019-03-28

Family

ID=61240223

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901389XA SG11201901389XA (en) 2016-08-25 2017-08-25 Combination therapy with glutaminase inhibitors

Country Status (12)

Country Link
US (2) US10278968B2 (en)
EP (1) EP3503886A4 (en)
JP (1) JP2019526560A (en)
KR (1) KR20190040302A (en)
CN (1) CN110139649A (en)
AU (1) AU2017315446A1 (en)
BR (1) BR112019003533A2 (en)
CA (1) CA3034890A1 (en)
EA (1) EA201990567A1 (en)
MX (1) MX2019002108A (en)
SG (1) SG11201901389XA (en)
WO (1) WO2018039544A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211610T1 (en) 2012-11-16 2022-02-04 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
US10316030B2 (en) 2014-08-07 2019-06-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
KR20170132333A (en) 2015-04-06 2017-12-01 칼리테라 바이오사이언시즈, 인코포레이티드 Treatment of lung cancer with glutaminase inhibitor
US10258619B2 (en) 2015-10-05 2019-04-16 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
AU2017315446A1 (en) 2016-08-25 2019-03-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN109982703A (en) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 With the combination treatment of glutamine enzyme inhibitor
US11590122B2 (en) 2021-02-19 2023-02-28 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
KR20230001587A (en) * 2021-06-28 2023-01-05 연세대학교 산학협력단 A pharmaceutical composition for preventing or treating cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AU2002305926A1 (en) 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
JP4885122B2 (en) 2004-04-15 2012-02-29 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Proteolytic markers as diagnostic biomarkers for cancer, organ injury, and muscle rehabilitation / exercise overtraining
EP2255818B1 (en) 2008-02-19 2018-08-22 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012006506A1 (en) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
JP2013543009A (en) 2010-11-18 2013-11-28 デューテリア ファーマシューティカルズ， インコーポレイテッド 3-deutero-pomaridomide
CN103030597B (en) 2011-09-30 2014-10-01 南昌滨西科技有限公司 Kidney type glutaminase inhibitor as well as preparation method and application kidney type glutaminase inhibitor
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
CN108785305B (en) * 2011-11-21 2021-10-29 卡利泰拉生物科技公司 Heterocyclic inhibitors of glutaminase
JP6306592B2 (en) 2012-09-10 2018-04-04 セルジーン コーポレイション Methods for treating locally advanced breast cancer
HRP20211610T1 (en) * 2012-11-16 2022-02-04 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
ES2761951T3 (en) 2012-11-21 2020-05-21 Agios Pharmaceuticals Inc Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
BR112015012536A2 (en) 2012-12-03 2017-07-11 Calithera Biosciences Inc cancer treatment with heterocyclic glutaminase inhibitors
KR20160066554A (en) 2013-10-25 2016-06-10 파마싸이클릭스 엘엘씨 Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
US9687485B2 (en) 2014-06-13 2017-06-27 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
US10316030B2 (en) 2014-08-07 2019-06-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
WO2016077632A2 (en) * 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
AU2016243631B2 (en) 2015-03-30 2021-07-29 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
KR20170132333A (en) 2015-04-06 2017-12-01 칼리테라 바이오사이언시즈, 인코포레이티드 Treatment of lung cancer with glutaminase inhibitor
AU2017315446A1 (en) 2016-08-25 2019-03-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN109982703A (en) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 With the combination treatment of glutamine enzyme inhibitor
US20180055825A1 (en) 2016-08-25 2018-03-01 Yu Liang Treatment of cancer with inhibitors of glutaminase

Also Published As

Publication number Publication date
EA201990567A1 (en) 2019-08-30
JP2019526560A (en) 2019-09-19
EP3503886A1 (en) 2019-07-03
EP3503886A4 (en) 2020-07-22
WO2018039544A1 (en) 2018-03-01
US20180055843A1 (en) 2018-03-01
CA3034890A1 (en) 2018-03-01
US20190275038A1 (en) 2019-09-12
BR112019003533A2 (en) 2019-05-21
AU2017315446A1 (en) 2019-03-07
MX2019002108A (en) 2019-07-08
KR20190040302A (en) 2019-04-17
CN110139649A (en) 2019-08-16
US10278968B2 (en) 2019-05-07

Similar Documents

Publication Publication Date Title
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201811432WA (en) Rna for cancer therapy
SG11201909949XA (en) Targeted immunotolerance
SG11201901390TA (en) Tetracycline compounds and methods of treatment
SG11201901126UA (en) Combination therapy for cancer
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201908391XA (en) Methods for modulating an immune response
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201803906PA (en) Control of cellular redox levels
SG11201804384UA (en) Geometric configurations for gastric residence systems
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201810454YA (en) Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201810196RA (en) Cancer treatments